Thrivent Financial For Lutherans Cytom X Therapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$4.32 - $6.43 $56,916 - $84,715	-13,175 Closed	0 $0
Q2 2021 Aug 19, 2021	SELL	$6.33 - $9.91 $130,841 - $204,839	-20,670 Reduced 61.07%	13,175 $83,000
Q1 2021 May 17, 2021	SELL	$6.6 - $9.0 $374,596 - $510,813	-56,757 Reduced 62.64%	33,845 $262,000
Q3 2020 Nov 10, 2020	BUY	$6.55 - $8.83 $269,060 - $362,718	41,078 Added 82.95%	90,602 $602,000
Q1 2020 May 15, 2020	BUY	$3.61 - $8.6 $178,781 - $425,906	49,524 New	49,524 $380,000

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $75.8M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.